Patents by Inventor Anne-Catherine Fluckiger
Anne-Catherine Fluckiger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230272013Abstract: The present disclosure provides compositions and methods useful for treating HCMV infection. As described herein, the compositions and methods are based on development of immunogenic compositions that include virus-like particles (VLPs) which comprise one or more Moloney Murine leukemia virus (MMLV) core proteins and include one or more HCMV epitopes, such as, for example, from HCMV envelope glycoproteins gB and/or gH and/or tegument protein pp65. Among other things, the present invention encompasses the recognition that a combination of antigens (e.g., envelope glycoproteins and structural proteins) can lead to beneficial immune responses, for example that include both a humoral response (e.g., production of neutralizing antibodies) and a cellular response (e.g., T-cell activation).Type: ApplicationFiled: February 11, 2022Publication date: August 31, 2023Inventors: David E. Anderson, Anne-Catherine Fluckiger
-
Publication number: 20230149537Abstract: Provided herein are vaccines including coronavirus antigens and E6020, as well as methods of mitigation of coronavirus infection by administering those vaccines.Type: ApplicationFiled: April 6, 2021Publication date: May 18, 2023Applicants: Eisai R&D Management Co., Ltd., Variation Biotechnologies Inc.Inventors: Fabian GUSOVSKY, Lynn HAWKINS, Sally ISHIZAKA, David Evander ANDERSON, Anne-Catherine FLUCKIGER
-
Publication number: 20220233682Abstract: The present disclosure provides compositions and methods useful for preventing and/or treating coronavirus infection. As described herein, the compositions and methods are based on development of immunogenic compositions that include virus-like particles (VLPs) which comprise one or more Moloney Murine leukemia virus (MMLV) core proteins and include a spike protein from the Beta variant of SARS-Cov-2.Type: ApplicationFiled: January 12, 2022Publication date: July 28, 2022Inventors: David Evander Anderson, Anne-Catherine Fluckiger
-
Patent number: 11253587Abstract: The present disclosure provides compositions and methods useful for preventing and/or treating coronavirus infection. As described herein, the compositions and methods are based on development of immunogenic compositions that include virus-like particles (VLPs) which comprise one or more Moloney Murine leukemia virus (MMLV) core proteins and include one or more coronavirus epitopes, such as, for example, from SARS-Cov-2 spike protein.Type: GrantFiled: March 30, 2021Date of Patent: February 22, 2022Assignee: Variation Biotechnologies Inc.Inventors: David Evander Anderson, Anne-Catherine Fluckiger
-
Patent number: 11248026Abstract: The present disclosure provides compositions and methods useful for treating HCMV infection. As described herein, the compositions and methods are based on development of immunogenic compositions that include virus-like particles (VLPs) which comprise one or more Moloney Murine leukemia virus (MMLV) core proteins and include one or more HCMV epitopes, such as, for example, from HCMV envelope glycoproteins gB and/or gH and/or tegument protein pp65. Among other things, the present invention encompasses the recognition that a combination of antigens (e.g., envelope glycoproteins and structural proteins) can lead to beneficial immune responses, for example that include both a humoral response (e.g., production of neutralizing antibodies) and a cellular response (e.g., T-cell activation).Type: GrantFiled: August 22, 2017Date of Patent: February 15, 2022Assignees: Variation Biotechnologies Inc., Sorbonne UniversitéInventors: David E. Anderson, Anne-Catherine Fluckiger, David Klatzmann, Charlotte Dalba-Fribert
-
Publication number: 20210353741Abstract: The present disclosure provides compositions and methods useful for preventing and/or treating coronavirus infection. As described herein, the compositions and methods are based on development of immunogenic compositions that include virus-like particles (VLPs) which comprise one or more Moloney Murine leukemia virus (MMLV) core proteins and include one or more coronavirus epitopes, such as, for example, from SARS-Cov-2 spike protein.Type: ApplicationFiled: March 30, 2021Publication date: November 18, 2021Inventors: David Evander Anderson, Anne-Catherine Fluckiger
-
Patent number: 10456460Abstract: The present disclosure provides compositions and methods useful for preventing and treating Zika virus infection. As described herein, the compositions and methods are based on development of immunogenic compositions that include virus-like particles (VLPs) which comprise one or more Moloney Murine leukemia virus (MMLV) core proteins and include one or more Zika epitopes, such as, for example, from Zika envelope glycoprotein E and the Zika structural protein NS1 including variants thereof.Type: GrantFiled: October 27, 2017Date of Patent: October 29, 2019Assignee: Variation Biotechnologies Inc.Inventors: David E. Anderson, Anne-Catherine Fluckiger
-
Publication number: 20180289794Abstract: The present disclosure provides compositions and methods useful for preventing and treating Zika virus infection. As described herein, the compositions and methods are based on development of immunogenic compositions that include virus-like particles (VLPs) which comprise one or more Moloney Murine leukemia virus (MMLV) core proteins and include one or more Zika epitopes, such as, for example, from Zika envelope glycoprotein E and the Zika structural protein NS1 including variants thereof.Type: ApplicationFiled: October 27, 2017Publication date: October 11, 2018Inventors: David E. Anderson, Anne-Catherine Fluckiger
-
Publication number: 20170349634Abstract: The present disclosure provides compositions and methods useful for treating HCMV infection. As described herein, the compositions and methods are based on development of immunogenic compositions that include virus-like particles (VLPs) which comprise one or more Moloney Murine leukemia virus (MMLV) core proteins and include one or more HCMV epitopes, such as, for example, from HCMV envelope glycoproteins gB and/or gH and/or tegument protein pp65. Among other things, the present invention encompasses the recognition that a combination of antigens (e.g., envelope glycoproteins and structural proteins) can lead to beneficial immune responses, for example that include both a humoral response (e.g., production of neutralizing antibodies) and a cellular response (e.g., T-cell activation).Type: ApplicationFiled: August 22, 2017Publication date: December 7, 2017Inventors: David E. Anderson, Anne-Catherine Fluckiger
-
Patent number: 9833505Abstract: The present disclosure provides compositions and methods useful for preventing and treating Zika virus infection. As described herein, the compositions and methods are based on development of immunogenic compositions that include virus-like particles (VLPs) which comprise one or more Moloney Murine leukemia virus (MMLV) core proteins and include one or more Zika epitopes, such as, for example, from Zika envelope glycoprotein E and the Zika structural protein NS1 including variants thereof.Type: GrantFiled: July 6, 2017Date of Patent: December 5, 2017Assignee: Variation Biotechnologies Inc.Inventors: David E. Anderson, Anne-Catherine Fluckiger
-
Patent number: 9777043Abstract: The present disclosure provides compositions and methods useful for treating HCMV infection. As described herein, the compositions and methods are based on development of immunogenic compositions that include virus-like particles (VLPs) which comprise one or more Moloney Murine leukemia virus (MMLV) core proteins and include one or more HCMV epitopes, such as, for example, from HCMV envelope glycoproteins gB and/or gH and/or tegument protein pp65. Among other things, the present invention encompasses the recognition that a combination of antigens (e.g., envelope glycoproteins and structural proteins) can lead to beneficial immune responses, for example that include both a humoral response (e.g., production of neutralizing antibodies) and a cellular response (e.g., T-cell activation).Type: GrantFiled: November 9, 2012Date of Patent: October 3, 2017Assignee: Variation Biotechnologies Inc.Inventors: David E. Anderson, Anne-Catherine Fluckiger
-
Publication number: 20140308308Abstract: The present disclosure provides compositions and methods useful for treating HCMV infection. As described herein, the compositions and methods are based on development of immunogenic compositions that include virus-like particles (VLPs) which comprise one or more Moloney Murine leukemia virus (MMLV) core proteins and include one or more HCMV epitopes, such as, for example, from HCMV envelope glycoproteins gB and/or gH and/or tegument protein pp65. Among other things, the present invention encompasses the recognition that a combination of antigens (e.g., envelope glycoproteins and structural proteins) can lead to beneficial immune responses, for example that include both a humoral response (e.g., production of neutralizing antibodies) and a cellular response (e.g., T-cell activation).Type: ApplicationFiled: November 9, 2012Publication date: October 16, 2014Applicant: Variation Biotechnolgies, Inc.Inventors: David E. Anderson, Anne-Catherine Fluckiger
-
Patent number: 6319493Abstract: A method is provided for treating tumors, e.g., lymphocytic leukemias, which comprises administering to a mammal an effective amount of interleukin-10.Type: GrantFiled: April 19, 2000Date of Patent: November 20, 2001Assignee: Schering CorporationInventors: Paulo J. Vieira, Kevin W. Moore, Rene de Waal Malefyt, Jan E. de Vries, Anne-Catherine Fluckiger, Jacques Banchereau
-
Patent number: 6106823Abstract: A method is provided for treating tumors, e.g., lymphocytic leukemias, which comprises administering to a mammal an effective amount of interleukin-10.Type: GrantFiled: December 17, 1993Date of Patent: August 22, 2000Assignee: Schering CorporationInventors: Paulo J. Vieira, Kevin W. Moore, Rene de Waal Malefyt, Jan E. de Vries, Anne-Catherine Fluckiger, Jacques Banchereau